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Prevalence of Erectile Dysfunction in Male Cancer Survivors: a Systematic 
Review and Meta-Analysis of Cross-Sectional Studies
Abstract
Background: Normal sexual function is one of the most improtant aspects of well 
being and quality of life. In male cancer survivors normal sexual function may be 
problematic and normal erectile function may be compromised due to issues associated 
with cancer disease and treatment. However, the prevalence of erectile dysfunction (ED) 
in male cancer survivors across cancer types has not been systematically analysed. 
Aim: We conducted a systematic review and meta-analysis to estimate the prevalence 
of ED in all types of cancer and identify characteristics associated with ED in cancer 
survivors. 
Design and Setting: Systematic review and meta-analysis of cross-sectional studies.
Method: We searched four electronic databases – Medline Cinhal, PsychInfo and 
Embase – targeting reports published until 1st of February 2020. All retrospective or 
prospective studies reporting the prevalence of ED in male patients with cancer and 
using a validated tool for the detection of ED (e.g. the International Index of Erectile 
Function, IIEF-5) were included in this review. Random-effects meta-analysis (MA) 
model was used to pool the prevalence of ED as absolute estimates at three different 
stages (i.e., healthy, at diagnosis, and after treatment stages). A univariate MA 
regression including the three-level group variable as the only independent variable was 
used to assess the difference of prevalence of ED across the three groups. Further MA 
were conducted for studies involving patients at diagnosis and after treatment and 
statistical inferences were made with setting for multiple testing controlling for false 
discovery rate less than 0.05. Graphical comparisons of the prevalence of ED across 
these two stages of cancer treatment were given by a classic forest plot.
Results: 1301 studies were assessed for inclusion. Of those, 141 were potentially 
eligible and subsequently scrutinizedscrutinised in full text. We included 43 studies 
with a total of 19,329 participants. Overall the pooled data of the included studies 
showed an ED prevalence of 40.72% (95%CI: 31.80-50.29) in cancer patients, with 
prevalence of 28.60% (95%CI: 12.10%-53.83%) at time of diagnosis and 42.70% 
(95%CI: 32.97%-53.03%) after treatment, with significant difference between these 






















Conclusion: ED is particularly high in male cancer survivors and was found to be 
associated with cancer treatment, cancer site, and age. 
Keywords: Erectile Dysfunction; Male Cancer; Systematic Review; Meta-Analysis. 
How this fits in
 In male cancer survivors, normal sexual function may be disturbed due to occurrence 
of erectile dysfunction.
 Our systematic literature review and meta-analysis reported a prevalence of 40.72% 
of erectile dysfunction in cancer survivors, with prevalence being somewhat higher in 
studies that focused on reporting prevalence after cancer treatment with 42.70%.
 The reasons of high occurrence of erectile dysfunction in male cancer survivors is 
multimodal and it includes a variety of factors including psychological and physical 
ones. 
 Clinicians should be aware that erectile dysfunction has a large effect on the quality 






















Cancers located in the pelvic region represent more than a quarter of all newly 
diagnosed cancers worldwide in men.1 This localisation of cancer has also been 
associated with long term severe sexual dysfunction in at least half of all patients.2 
Erectile dysfunction (ED), the inability to obtain or maintain an erection that allows for 
sexual intercourse, is one of the most distressing consequences of cancer diagnosis and 
treatment in men.3 
Erectile dysfunction has a complex aetiology influenced by cancer in both direct 
and indirect ways. Men diagnosed with prostate cancer, the second most common type 
of cancer (except for non-melanoma skin cancer) in men,1 are expected to have the 
same risk factors (cardiovascular disease and metabolic disorders) for ED when 
compared with cancer-free age matched men. However, in men with prostate cancer, 
risks for ED are increased given higher incidence of lower urinary tract symptoms and 
psychological distress.4,5 Indirect pathways, mostly associated with cancer treatment 
modalities (surgery, radio- and chemotherapy and hormone treatment) seem to be the 
most common cause.6,7 
Moreover, few men are able to achieve normal erection following pelvic surgery, 
with studies noting that even in men with excellent baseline erections, less than one 
quarter retained or recovered the erection quality prior to treatment. Pelvic surgeries 
most associated with ED are radical prostatectomy, radical cystectomy and low anterior 
or abdominoperineal resections.8 Furthermore, the results from a 12 year follow up 
study showed that 84% and 80% of men with prostate cancer who had radical 
prostatectomy or were under active surveillance reported ED, respectively, compared 
to 43% in the matched control group.9 Similar results have been reported for men who 
had treatment for other types of pelvic cancer such as anal, rectal or bladder cancer.10-
15 However, it is noteworthy that ED is not only prevalent in men with pelvic cancers 
but may also be the result of intensive chemotherapy  or radiotherapy, causing 
hypogonadism or pelvic nerve damage. Studies have shown ED also after lung cancer, 
haematological malignancies and head and neck tumours.16-18 
Sexuality and intimacy are important aspects of quality of life and may also reduce 
some of the psychosocial distress associated with the cancer diagnosis. In this light it 
has been reported that maintaining a normal sexual function in men with cancer can be 
important to help relieve suffering.19,20   Given the growing incidence of cancer globally 





















survivors, questions of quality of life post-diagnosis and treatment are more and more 
relevant. However, studies focusing on ED in cancer survivors are rare, and mostly 
focused on cancer localisations in the pelvic region, making prevalence estimates of 
ED in cancer survivors rare. Providing pooled estimates of the prevalence of ED as well 
as its associations should provide important information not only on the scale of the 
issue but also help clinicians working with cancer survivors to easily identify patients 
who are at risk of ED but also to provide comprehensive cancer care that is associated 
long-term quality of life of cancer survivors.
 Therefore, the aim of this systematic review and meta-analysis (MA) was to 
examine the available studies and provide pool estimates for ED prevalence in relation 
to all cancer sites and identify characteristics associated with ED in cancer survivors. 
To our knowledge this is the first study of its kind.  
Material and methods
Search strategy
We searched four electronic databases – Medline Cinhal, PsychInfo and Embase 
– targeting reports published until 1st of February 2020. The search strategy 
included terms reported in Supplementary Table 1. 
The references of retrieved articles together with the proceedings of relevant 
conferences were hand-searched in order to identify other potentially eligible studies 
for inclusion in the analysis missed by the initial search or any unpublished data. 
The literature search, assessment of inclusion and exclusion criteria, quality of 
studies and extraction of data were independently undertaken and verified by two 
investigators (DP, TX). The results were then compared and, in case of discrepancies, 
a consensus was reached with the involvement of a third investigator (LS). There was 
no language restriction.
 
Type of studies, inclusion and exclusion criteria
All retrospective or prospective studies reporting the prevalence of ED in male 
patients with cancer and using a validated tool for the detection of ED (e.g. the 
International Index of Erectile Function, IIEF-5) were included in this review. We 






















Types of outcome measures
All outcomes were defined prior to the literature search. The primary outcome 
was the prevalence of ED across cancer treatment relevant stages (i.e., healthy, at 
diagnosis, and after treatment stages).
 
Data extraction and statistical analyses
 
For all included studies, we generated descriptive tables for population and study 
characteristics. We recorded the first author, publication year, country of the 
investigators, sample size, age, method of assessment of ED and cancer type and site. 
Furthermore, number of ED patients among case and control groups, BMI, hormonal 
levels, smoking, hypertension, diabetes, dyslipidemia and cardiovascular diseases 
were recorded. All statistical analyses based on these data were performed using R 
(version 3.6.1).21 
For the included studies at the three different stages (i.e., healthy, at diagnosis, 
and after treatment stages), random-effects meta-analysis model with the between-
study heterogeneity parameter estimated by DerSimonian-Laird (DL) method 22 was 
used to pool the prevalence of ED as absolute estimates (in %) with their 95% 
confidence intervals (CIs) for each of three stages of patients. A univariate MA 
regression including the three-level group variable for healthy/diagnosis/treatment 
stages as the only independent variable was used to assess the difference of 
prevalence of ED across the three stages. A scatter plot with point and confidence 
interval estimates of prevalence of ED across three different groups of patients are 
illustrated. Publication bias was assessed by a visual inspection of funnel plots and 
calculating the Egger bias test.23 In case of publication bias (p<0.10), we planned to 
apply the trim and fill-analysis 24 for overcoming this bias. 
Further MA were conducted for the 40 studies only involving patients at diagnosis 
and after treatment (i.e., excluding healthy control). Graphical comparisons of the 
prevalence of ED across these two stages of cancer treatment were given by a classic 
forest plot. Heterogeneity across these 40 studies involving the two cancer treatment 





















I2 >50% or p<0.05 for testing the Chi2-distributed Q statistic for between-studies 
heterogeneity (a high value of Q would result in a high value of I2 since I2 = (Q-
K+1)/Q where K is the number of studies).25 In case of high heterogeneity of the 
prevalence of ED and having at least 10 studies for the outcome, we used, as possible 
predictors for MA regression analyses: stage, continent, mean age, range of age, 
method of ED assessment, cancer site, standard deviation of age, proportion of 
patients underwent radiotherapy, proportion of patients with diabetes, proportion of 
patients underwent chemotherapy. The plots of study count distribution for each of 
the above moderators across their observed values are given. Univariate MA 
regression model for each moderator was fit. The stage predictor as well as the 
significant moderators screened out by these univariate MA regression analyses were 
used as potential predictors to fit a multiple MA regression with manual variable 
selection procedure applied. The conclusions by the final multiple MA regression 
model were drawn with multiple testing concern by controlling for false discovery 
rate (FDR).26 Back-transformed estimated prevalence values of ED with 95% C.I. for 
studies with different levels of predictor variables in the final multiple MA regression 
model were given. 
For all MA regression, we applied the logit transformation to the observed 
prevalence across primary studies to make the transformed prevalence follow a 
normal distribution, and the MA regression analysis is based on the transformed scale.
Assessment of study quality
Study quality was assessed by two investigators (DP, LS) using the Newcastle-Ottawa 
Scale (NOS).27,28 This scale has been adapted from the Newcastle-Ottawa Quality 
Assessment Scale for cohort studies to perform a quality assessment of cross-sectional 
studies for the systematic review.27,28 A third reviewer was available for mediation 
(NV). The NOS assigns a maximum of 9 points based on three quality parameters: 
selection, comparability, and outcome.
Results
The electronic search yielded, after de-duplication, 1301 studies that were 
assessed for inclusion in the review. Of those, 141 were potentially eligible and 























 Amongst the relevant studies, 98 failed to meet the inclusion criteria and were 
excluded from this overview. Of these, 37 used no validated tools for ED assessment, 
36 had no useful data on ED prevalence, 18 were longitudinal studies, 4 had no data 
on the association between ED and cancer and 3 were double publications.
Included studies
The 43 studies, 36 prospective and 7 retrospective, included a total of 19,329 
participants. The majority of the studies (n=25) were conducted in Europe, 6 in North 
America, 6 in Asia, 5 in Middle East and 1 in Oceania. The most affected sites were: 
prostate and rectum (12 studies each), testis (6), haematological (5), multiple sites (3), 
colorectal (2), and penis, colon and anus (1 each).
The median quality of the studies was 4.97 (range: 3-7), indicating an overall good 
quality of the studies, according to the NOS (Supplementary Table 2). In particular, 
the majority of the studies (18) scored 5, followed by 11 studies with 4. Only 3 studies 
scored 3 while 6 and 5 studies scored 6 and 7 respectively.
Meta-analysis on Prevalence of ED across three stages (i.e., healthy, at diagnosis, 
and after treatment stages)
Distribution of study counts and the corresponding pooled prevalence of ED at 
the three different stages are given in Table 1. The pooled prevalence of ED at the 
stage of after treatment was significantly different from that of healthy control by the 
univariate MA regression analysis with dummy variables for stage (p = 0.0322).
To compare prevalence of ED among patients in the two cancer treatment stages 
with that of healthy control people, we also illustrate the pooled prevalence of these 
three groups of people in Figure 1, with the pooled prevalence of ED given in red 
square and the corresponding CI given in red extending line (blue circles are centered 
at the prevalence of ED reported in each of the included primary studies with circle 





















Small study effect (including publication bias) was not found among the included 
studies and the trim and fill analysis did not modify our results. Figure 2 shows the 
funnel plot, with non-significant Egger’s test result for funnel plot asymmetry (p = 
0.4418).
Meta-analysis on Prevalence of ED across the two cancer treatment stages (i.e., 
at diagnosis, and after treatment stages) 
Pooling the data of the 40 studies of cancer patients only (i.e., excluding 3 studies 
of healthy controls), we found an overall prevalence of 40.72% (95%CI: 31.80-50.29) 
with a high degree of overall heterogeneity (I2=98%; p<0.0001). Figure 3 shows the 
prevalence of ED among cancer patients.
To locate the potential predictors that account for the very high heterogeneity of 
prevalence of ED among all the primary studies involving cancer patients in the two 
treatment stages, MA regression analyses were conducted with ten predictors used. 
Distribution plots of Study Count for each of the 10 possible predictors are given in 
Supplementary Figure 2. Study counts of these 10 possible predictors for the ED 
prevalence among cancer patients and p-value for continuous predictor (or smallest 
p-value for the dummy variables of categorical predictor) in the univariate MA 
regression analysis are given in Table 2. The results by the univariate MA regression 
showed that the following mean age and cancer site are variables that are significantly 
associated with the ED prevalence.
After a manual variable selection accounting for the multicollinearities of the 
predictors, a parsimonious MA regression model was built to predict the highly 
heterogeneous ED prevalence. Regression coefficient estimates of this prediction 
model are given in Table 3. This model only included two predictors, Stage and Cancer 
Site. Since both of them are categorical variables, dummy variables are created to 
represent them. The reference level for Stage is selected as “at diagnosis”, and the 
reference level for Cancer Site is selected as “prostate” since prostate cancer has the 
highest count (12) in the collected primary study data (this count is same as the rectum 
cancer) and prostate cancer is a common cancer in urology. Both predictors are 
significant controlling for false discovery rate less than 5% in this MA regression model 





















significantly associated with factors of stage and cancer site. The interpretations of 
those significant regression coefficients are given as follows: study-reported odds of 
ED at after-treatment stage is estimated to be 2.4823 (i.e., exponential of 0.9092) times 
of that at diagnosis stage controlling for other covariates (95% C.I.: 1.3054 to 4.7204; 
adjusted p-value controlling for FDR: 0.0204); study-reported odds of ED for patients 
with colon cancer is estimated to be 0.23 (i.e., exponential of -1.4697) times of that for 
patients with prostate cancer controlling for other covariates (95% C.I.: 0.0697 to 
0.7587; adjusted p-value controlling for FDR: 0.0434); study-reported odds of ED for 
patients with lymphoma cancer is estimated to be 0.2530 (i.e., exponential of -1.3744) 
times of that for patients with prostate cancer controlling for other covariates (95% C.I.: 
0.0756 to 0.8470; adjusted p-value controlling for FDR: 0.0473); study-reported odds 
of ED for patients with multiple cancers is estimated to be 0.1041 (i.e., exponential of 
-2.2625) times of that for patients with prostate cancer controlling for other covariates 
(95% C.I.: 0.0419 to 0.2586; adjusted p-value controlling for FDR: < .0001); study-
reported odds of ED for patients with penis cancer is estimated to be 0.1725 (i.e., 
exponential of -1.7574) times of that for patients with prostate cancer controlling for 
other covariates (95% C.I.: 0.0394 to 0.7553; adjusted p-value adjusted p-value 
controlling for FDR: 0.0433); study-reported odds of ED for patients with testis cancer 
is estimated to be 0.1353 (i.e., exponential of 2.0001) times of that for patients with 
prostate cancer controlling for other covariates (95% C.I.: 0.0730 to 0.2508; adjusted 
p-value controlling for FDR: < .0001).
The R2 value of this MA regression is as high as 75.70%, indicating that this MA 
regression model already accounts for 75.70% heterogeneity of the ED prevalence 
reported by the 40 studies involving studies of cancer patients. The back-transformed 
estimated prevalence values of ED for studies with patients of different cancers at the 
two stages by this MA regression are given in Table 4.
Discussion
Summary
In our systematic review our search yielded 1301 individual studies, out of which 
43 studies with overall 19,329 participants were included in the analysis. Our study 
provides pooled estimates for ED in cancer survivors across all cancer sites providing 
synthesized data of this kind for the first time. Overall the pooled data of the included 





















with prevalence of 28.60% (95%CI: 12.10%-53.83%) at time of diagnosis and 42.70% 
(95%CI: 32.97%-53.03%) after treatment, across cancer locations.
Strengths and limitations
This systematic review and meta-analysis provides a comprehensive overview of 
evidence on the prevalence of ED in cancer survivors in general with studies using 
validated self-reported methods. 
Limitations of our analysis include the inherent limitations from the included 
studies. Study populations were on average over 60 years old, which may have 
contributed to the prevalence as ED risks increase with age. Similar is the 
overrepresentation of cancer sites in the pelvic area. Again, due to the small number of 
primary studies that provide complete clinical and biological (e.g. serum testosterone 
or estradiol levels) features of the participants, we were not able to run some meta-
regression analyses using well-known independent risk factors for ED (such as 
dyslipidemia, hypertension, diabetes mellitus and depression) as moderators of our 
findings. Lastly, the results pertaining to cancer survivors with multiple cancer sites 
need to be taken with caution given that there were only 3 primary studies that were 
included in the analysis. 
Comparison with existing literature
Meta-analyses of studies reporting prevalence levels of ED in healthy men are rare 
and mostly focusing on samples of Asian men. These studies report that ED prevalence 
in individual studies has been reported from 2 to 82%, differing among age groups and 
how ED has been assessed. Generally, lowest reports have been found among younger 
men between 20 and 29 years old with 15.1% (12.2–18.1), while the highest have been 
found in the groups of 60 and over with 70.0% (62.3–77.7).29 Studies have noted that 
self-report leads to lower estimates than measuring by a standardized questionnaire. 
Overall pooled estimate for ED prevalence has been reported at 49.69% (95% CI = 
39.29–60.10) for Chinese samples.30
Most studies included in our meta-analysis focused on cancers located in the pelvic 
region (prostate and rectum) and testis, where the effects would be expected to be 





















Androgen-deprivation therapy (ADT) which is used in prostate cancer management 
leads to ED in most men who had not dysfunction prior to therapy.31-33 Various 
chemotherapeutic agents may induce microangiopathy and vascular insufficiency in the 
corpus cavernosum of the penis as well as neurotoxicity that may result in ED.34 In a 
study of more than 260 men on platinum-based chemotherapy, 40% were reported to 
have ED on standardized questionnaires, which corresponds to the pooled data from 
our analysis.35 ED is also a common finding after radiation therapy for prostate cancer 
with varying incidence reported in studies depending on the dose, technique, associated 
treatments and time post-treatment, with brachytherapy showing lower rates of ED 
compared to external-beam radiation therapy in some studies.36-37
Surgical cancer treatment in the pelvic area may also lead to postoperative sexual 
dysfunction, depending both on the surgical techniques and methods used in assessing 
ED postoperatively. In one study more than 90% of patients who had radical 
prostatectomy reported lower scores on the IIEF-5 than before surgery,38 with an Italian 
based study reporting that reaching perioperative levels does not equal patient 
satisfaction, with little over one quarter of patients who reported preoperative scores 
reported being satisfied. Only men who achieved scores higher than 22, as measured 
by the IIEF, and returned to the same levels postoperatively were also satisfied with 
their sexual function.39 Similarly, 86% of men who had radical cystectomy were not 
able to achieve vaginal penetration and studies report between 10 and 50% of men 
having sexual dysfunction following colorectal surgery, where the proposed 
mechanism may lie in the injury to the hypogastric plexus. In testicular cancer survivors, 
a study measuring blood flow and erectile hemodynamics using duplex 
ultrasonography reported that 12 months after treatment there were no differences 
between men with or without hypogonadism, suggesting an hyperadrenergic mediated 
causes of ED.40  
Sexual function may be influenced by systemic chemo- or radiation therapy, as 
well as by psychological factors such as depression, anxiety, low self-esteem or issues 
with body image, which are known conditions in all cancer patients and survivors, 
regardless of the primary cancer site.41-47 However, very few studies examine the effects 
of cancer sites outside of the pelvic area on the overall sexual function or ED, 
specifically, in men. A meta-analysis on sexual functioning in male lymphoma 
survivors reported prevalence of sexual dysfunction between 20 and 40%.48 Anecdotal 





















this is the most prevalent cancer in men globally, there is still no research on sexual 
function in men lung cancer patients or survivors, as most of the focus is on short-term 
survival rather than post-treatment quality of life.49 
 
Implications for research and/or practice
Our analysis showed high prevalence of ED in cancer survivors at various points 
and across cancer types. As the aetiology of ED in cancer survivors is multimodal and 
it includes a variety of factors including psychological and physical ones. The results 
should improve the visibility of this issue and allow health care professionals to more 
easily identify cancer survivors under higher risk of ED. Moreover, it is important that 
clinicians be aware of the impact of ED on quality of life and mental health of cancer 
survivors, especially as sexuality and intimacy may reduce some of the psychosocial 
issues associated with receiving a cancer diagnosis.19,50 Various therapeutic modalities 
exist and health care providers should facilitate an open exchange with patients before 
cancer treatment and manage expectations. Here the primary care physicians are of 
great importance given their role in follow through during cancer care and beyond. As 
men are generally less prone to discuss sexual health problems in a clinical setting, 
clinicians should routinely and proactively ask about sexual health and recognize and 
acknowledge any concerns, which may increase the patient’s satisfaction and improve 
the doctor-patient relationship.51  
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Table 1: Study Count and Pooled Prevalence of ED across Three Stages 
Healthy 
Control
At Diagnosis After Treatment Total





250 782 2794 3826
Pooled sample 
size











* indicates that the ED prevalence among cancer patients after treatment is 
significantly different from that of healthy control at level 0.05 (p = 0.0322; this can 
also be seen by the fact that the point estimate of ED prevalence for healthy control, 






















Table 2: Study Count of the 10 Possible Predictors for the ED Prevalence and P-
value for the Uni-predictor (or Smallest P-value for the Uni-predictor Dummy 






Stage 40 0.6210 (-0.5253, 1.7673) 0.2883
Continent 40 1.2655 (-0.3051, 2.8362) 0.1143
Mean age 40 0.0503 (0.0243, 0.0762) 0.0002*
Range of age 40 0.0057 (-0.0210, 0.0325) 0.6739
Assessment method of 
ED
40 1.5236 (-0.1845, 3.2316) 0.0804




Standard deviation of 
age
17 -0.0078 (-0.0733, 0.0576) 0.8144
Proportion of patients 
underwent radiotherapy 





















Proportion of patients 
with diabetes
12 -3.6361 (-19.1360, 
11.8639)
0.6457
Proportion of patients 
underwent 
chemotherapy
12 0.1348 (-1.9925, 2.2621) 0.9012
Note: significance code controlling for type I error rate less than 0.05 and 






















Table 3: A prediction model for the highly heterogeneous ED prevalence
Regression Coefficients Estimate Standard 
error
z P-value Adjusted P-
value 
Intercept -0.5380 0.2720 -1.9778 0.0479 0.0659
Stage: After Treatment 0.9092 0.3279 2.7726 0.0056 0.0204 *
Cancer site: Colon -1.4697 0.6089 -2.4136 0.0158 0.0434 *
Cancer site: Colorectal 0.9628 0.4856 1.9830 0.0474 0.0744
Cancer site: 
Haematologic
-0.0742 0.4759 -0.1560 0.8761 0.9637
Cancer site: Lymphoma -1.3744 0.6165 -2.2293 0.0258 0.0473 *
Cancer site: Multiple -2.2625 0.4643 -4.8726 <.0001 <.0001 ***
Cancer site: Penis -1.7574 0.7535 -2.3324 0.0197 0.0433 *
Cancer site: Anus 0.1397 0.9449 0.1478 0.8825 0.8825
Cancer site: Rectum -0.3761 0.2919 -1.2888 0.1975 0.2414
Cancer site: Testis -2.0001 0.3148 -6.3533 <.0001 <.0001 ***
Note: significance code controlling for false discovery rate (FDR) less than 
0.05 and greater than 0.01: ‘*’; significance code controlling for false discovery 





















Table 4: Back-transformed estimated prevalence values of ED with 95% C.I. 
for studies with patients of different cancers at the two stages by the predictive 
MA regression model
Cancer site At diagnosis After treatment
Prostate cancer 59.2% (48.7%, 68.9%) 78.3% (58.2%, 90.3%)
Colon cancer 25.0% (9.8%, 50.4%) 45.3% (18.6%, 75.0%)
Colorectal cancer 79.1% (61.8%, 89.9%) 90.4% (76.4%, 96.5%)
Haematologic cancer 57.4% (37.0%, 75.5%) 77.0% (53.9%, 90.5%)
Lymphoma cancer 26.8% (10.6%, 53.2%) 47.6% (19.9%, 77.0%)
Multiple cancer 13.1% (6.3%, 25.2%) 27.2% (11.8%, 51.2%)
Penis cancer 20.0% (5.7%, 50.7%) 38.3% (11.6%, 74.6%)
Anus cancer 62.5% (21.6%, 91.0%) 80.5% (37.9%, 96.6%)
Rectum cancer 49.9% (40.4%, 59.4%) 71.2% (53.9%, 83.9%)





















Figure 1: Comparisons of prevalence of ED among cancer patients and healthy 
control





















Figure 3: Prevalence of ED among cancer patients
